Illumina, Inc. (ILMN)
Health Care · Genomic sequencing and diagnostics
Illumina powers genetic discovery and precision medicine through industry-leading DNA sequencing platforms and genomic analytics software.
What Illumina, Inc. does
Illumina is a leader in DNA sequencing and genomic analysis technologies, providing instruments, reagents, and software for genetic research, clinical diagnostics, and precision medicine applications. The company serves research institutions, diagnostic laboratories, and healthcare providers worldwide, enabling advances in understanding human genetics and disease.
Themes: ["genomic sequencing"]
Fundamentals
- Price$193.76 as of 2026-07-09 close
- Market cap$29.3B as of 2026-07-10
- 1-year return+98.9% as of 2026-07-09 close
- P/E34.31 as of 2026-07-10
- Net margin+19.4% as of 2026-07-10
- Gross margin+66.7% as of 2026-07-10
- ROE+34.0% as of 2026-07-10
- Debt / equity0.74 as of 2026-07-10
- Revenue growth (YoY)+1.3% as of 2026-07-10
- Revenue CAGR (3y)-1.4% SEC XBRL
- Beta1.47 as of 2026-07-10
Key risks (from latest filing)
["Intense competition in genomic sequencing technology from established players and emerging competitors may pressure pricing and market share"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.